Fexapotide Triflutate Pivotal Phase 3 Study Results Presented and Discussed at American Urological Association Annual Meeting...
May 22 2018 - 10:00AM
Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to report
on a successful symposium discussing Nymox’s lead product candidate
Fexapotide Triflutate (FT) as a novel therapeutic option in BPH at
the Annual Meeting of the American Urological Association in San
Francisco, this past weekend.
Dr. Ronald Tutrone of Chesapeake Urology
Research Associates, Baltimore MD, and a principal investigator in
the trials, chaired the meeting and presented clinically relevant
therapeutic highlights from the trials. Following Dr. Tutrone’s
presentation, other panel members commented on their positive
experiences with the drug and answered questions from the audience.
The panel members included Dr. Mohamed Bidair, San Diego CA; Dr.
Ivan Grunberger, New York NY; Dr. Alan Hay, Salem OR and Dr. Susan
Kalota, Tucson AZ.
Dr. Tutrone said, "FT is a safe, effective and
much needed treatment for men who have BPH. This is a less than 5
minute treatment that every urologist can easily integrate into
their management of their BPH patients."
Dr. Hay commented: ”When and where FT is
approved, I anticipate it will quickly become the initial choice
for all men with BPH/LUTS. It is safe and simple to deliver. A
single injection has symptom relief on the order of current oral
medications; 2 injections give symptom relief on the order of
surgery. It is hard to think of a patient with BPH/LUTS who
wouldn’t benefit from up-front FT injection no matter what else is
planned for their disease. The ease of injection and the impeccable
safety profile further reinforce that point.”
Randall Lanham, one of Nymox's Directors, also
commented: “Having been with the Company for many years, it is now
very gratifying to witness the very positive responses we see from
an ever-larger audience of clinicians across the country.
Investigators have now presented data at five regional AUA meetings
in addition to this weekend’s national meeting and there was a
detailed peer reviewed publication of Phase 3 clinical trial
results earlier this year in the World Journal of Urology. These
are important milestones and events for the development of
Fexapotide."
Dr Grunberger added, "The positive response of
the AUA attendees to the data confirmed my belief that Fexapotide
Triflutate has the potential to position itself as a first line
therapy for BPH once approved."
Dr Kalota said, "I am very excited about the
data and look forward to the future when I can freely offer this to
my patients. The data has shown efficacy and safety, and my
personal experience with the injections demonstrated the ease of
injection and acceptability to the patients."
Dr Bidair added, "I believe that the ease of
administration of FT and virtual lack of safety concerns and side
effects will make it a significant addition to our armamentarium
for treating BPH."
Nymox's fexapotide has been shown to produce
long-term improvements in lower urinary tract symptoms associated
with benign prostatic hyperplasia (BPH), a problem that afflicts an
estimated 100 million or more men in the world. Fexapotide does not
cause the annoying side effects and risks found with available
treatments for BPH and has also been shown to lower the occurrence
of surgery for BPH. Fexapotide is also in development for low grade
prostate cancer.
For more information please contact
info@nymox.com or 800-936-9669.
Forward Looking Statements
To the extent that statements contained in this
press release are not descriptions of historical facts regarding
Nymox, they are forward-looking statements reflecting the current
beliefs and expectations of management made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995, including statements regarding the need for new options to
treat BPH and prostate cancer, the potential of Fexapotide to treat
BPH and prostate cancer and the estimated timing of further
developments for Fexapotide. Such forward-looking statements
involve substantial risks and uncertainties that could cause our
clinical development program, future results, performance or
achievements to differ significantly from those expressed or
implied by the forward-looking statements. Such risks and
uncertainties include, among others, the uncertainties inherent in
the clinical drug development process, including the regulatory
approval process, the timing of Nymox's regulatory filings, Nymox's
substantial dependence on Fexapotide, Nymox's commercialization
plans and efforts and other matters that could affect the
availability or commercial potential of Fexapotide. Nymox
undertakes no obligation to update or revise any forward looking
statements. For a further description of the risks and
uncertainties that could cause actual results to differ from those
expressed in these forward-looking statements, as well as risks
relating to the business of Nymox in general, see Nymox's current
and future reports filed with the U.S. Securities and Exchange
Commission, including its Annual Report on Form 20-F for the year
ended December 31, 2017, and its Quarterly Reports.
For Further Information Contact:Erik
DanielsenNymox Pharmaceutical
Corporation1-800-93NYMOXwww.nymox.com
Nymox Pharmaceutical (NASDAQ:NYMX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Nymox Pharmaceutical (NASDAQ:NYMX)
Historical Stock Chart
From Sep 2023 to Sep 2024